1. When Progress Looks Like a Daily Pill: The Complex Reality of Vorasidenib
Dr. Akanksha Sharma
Sutter Health
Patients with IDH-mutant low-grade gliomas have long faced uncertain control with chemo and radiation, which carry lasting side effects and don’t always stop recurrence. The 2024 approval of vorasidenib offers the first targeted oral therapy, giving patients a chance to stay well longer and delay harsher treatments.
3. Who Benefits From Vorasidenib? Understanding Ideal Candidates vs. Real-World Complexity
Dr. Akanksha Sharma
Sutter Health
Vorasidenib can greatly delay tumor growth for many people with grade 2 IDH-mutant gliomas, especially those who fit the INDIGO trial profile. But treatment decisions aren’t one-size-fits-all— as many patients fall into gray areas where factors like daily medication commitment, access to care, and tumor behavior guide a more personalized approach.
